Abstract
Observational studies and early clinical trials indicated that long-chain n-3 fatty acids have a role in prevention of coronary heart disease, specifically fatal coronary heart disease. Results of recent trials have been inconsistent, although the study designs, patient populations, and n-3 doses have been quite different. Some studies have called into question whether there is any benefit from n-3 fatty acid therapy in patients who are receiving guideline-based treatment since their coronary event. Other recent trials suggest that certain patient subgroups, specifically those with diabetes or metabolic syndrome, may derive a significant benefit. Also, the only clinical trial to show a reduction in nonfatal coronary events used a higher n-3 fatty acid dose than used in the other studies, which raises the question of whether more is better for certain clinical outcomes. Only further research can resolve these questions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 115-122 |
| Number of pages | 8 |
| Journal | Current Nutrition Reports |
| Volume | 1 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2012 |
| Externally published | Yes |
Keywords
- Alpha Omega
- Cardiovascular
- Cardiovascular disease
- Coronary heart disease
- DART
- DHA
- EPA
- GISSI-HF
- GISSI-Prevenzione
- Heart failure
- JELIS
- OMEGA
- Omega-3 fatty acids
- Prevention
- Randomized controlled trial
- SU.FOL.OM3
- n-3 fatty acids
ASJC Scopus subject areas
- Food Science
- Nutrition and Dietetics
Fingerprint
Dive into the research topics of 'Omega-3 Fatty Acids and Cardiovascular Disease Prevention'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS